A Comparison of Different Dosages of Intra-arterial and Intravenous Administered Prostaglandin E1 in Healthy Volunteers

1991 ◽  
pp. 58-71
Author(s):  
G. Rudofsky ◽  
B. A. Peskar
Keyword(s):  
Healthy Volunteers ◽  
Prostaglandin E1

scholarly journals Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion.

1995 ◽  
Vol 40 (3) ◽  
pp. 273-276 ◽  
Author(s):  
W. Cawello ◽  
A. Leonhardt ◽  
H. Schweer ◽  
HW Seyberth ◽  
R. Bonn ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Intravenous Infusion ◽  
Prostaglandin E1 ◽  
Dose Proportional

scholarly journals Does the VerifyNow P2Y12 assay overestimate “therapeutic response” to clopidogrel?

2014 ◽  
Vol 111 (06) ◽  
pp. 1150-1159 ◽  
Author(s):  
Vikram Khanna ◽  
Alex Hobson ◽  
Rand Mikael ◽  
Nalyaka Sambu ◽  
Nicola Englyst ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Healthy Volunteers ◽  
Prostaglandin E1 ◽  
Therapeutic Response ◽  
Platelet Reactivity ◽  
Adenosine Diphosphate ◽  
Therapeutic Effects ◽  
P2y12 Inhibitors ◽  
High Platelet Reactivity

SummaryIn contrast to short thrombelastography (s-TEG) which utilises adenosine diphosphate (ADP) alone, the VerifyNow P2Y12 assay (VN-P2Y12) additionally uses prostaglandin E1 (PGE1) as agonist to assess response to P2Y12 inhibitors. Based upon previous observations, we hypothesised that VN-P2Y12 overestimates the therapeutic effects of clopidogrel. Simultaneous assay with s-TEG and VN-P2Y12 was performed in 43 healthy volunteers and 170 patients either on or off clopidogrel. Furthermore, in 27 patients on clopidogrel 75 mg we compared the effects of adding 22 nM PGE1 to ADP on platelet aggregation in s-TEG to ADP alone. A higher proportion of individuals had a result indicating high platelet reactivity (HPR) with s-TEG than VN-P2Y12 in (i) 43 clopidogrel naïve volunteers (95.3% vs 81.4%, p = NS); (ii) 28 volunteers loaded with clopidogrel 600 mg (39.3% vs 10.7 %, p = < 0.01); (iii) 123 clopidogrel naïve patients (93.5% vs 78%, p = < 0.0001); (iv) 47 patients on clopidogrel 75 mg (42.6% vs 4.3%, p = < 0.0001). In 59 patients loaded with clopidogrel 600 mg/900 mg, a greater proportion had a “therapeutic response” with VN-P2Y12 compared to s-TEG, regardless of the threshold for defining HPR with VN-PY12 (P2Y12 reaction units ≥ 230 or 208). Furthermore, adding PGE1 to ADP in s-TEG potentiated the anti-aggregatory effects of clopidogrel compared with ADP alone. In conclusion, VN-P2Y12 overestimates the functional effects of clopidogrel in some individuals, possibly because it utilises PGE1 in addition to ADP. This could have implications for the ability of VN-P2Y12 to stratify patients as “responders” or “non-responders” to clopidogrel.

Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers

1999 ◽  
Vol 13 (6) ◽  
pp. 1230 ◽  
Author(s):  
B Schmekel ◽  
I Rydberg ◽  
B Norlander ◽  
K.n Sjöswärd ◽  
J Ahlner ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Stereoselective Pharmacokinetics

Estimation of 15O PET in healthy volunteers with automated ROI analysis by FineSRT

2005 ◽  
Vol 25 (1_suppl) ◽  
pp. S673-S673
Author(s):  
Ryo Takeuchi ◽  
Keiichi Matsumoto ◽  
Setsu Sakamoto ◽  
Yuhji Nakamoto ◽  
Michio Senda
Keyword(s):  
Healthy Volunteers
Sign in / Sign up

Export Citation Format

Share Document